CClinicalTrials.gg
Status unknownNCT05636163Updated Dec 5, 2022

Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting

An observational study in Hemophilia A, sponsored by Qianfoshan Hospital. Status unknown at 1 site in China. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by Qianfoshan Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
18 Years to 70 Years
Sex
Male
01

Study summary

By comparing the incidence of PONV, the dosage of postoperative antiemetic drugs, the postoperative VAS score and the utilization rate of PCIA of hemophilia A patients in the NLR≥2 and NLR\<2 groups, investigators could find out the high value in the diagnosis of hemophilia A, which is helpful to guide the clinical diagnosis and treatment of hemophilia A.

Read the detailed description

Hemophilia arthropathy is a debilitating complication of hemophilia that occurs primarily in severe forms with recurrent spontaneous intra-articular hemorrhage, with the knee being the most commonly affected joint. Currently, total knee arthroplasty is the standard treatment for end-stage hemophilic arthropathy. Due to the special disease of hemophilia, general anesthesia is often chosen as the preferred anesthesia method, and the risk of bleeding is lower than that of neuraxial anesthesia. However, 20 to 30 percent of surgical patients suffer from post-operative nausea and vomiting after general anesthesia. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio have been suggested as parameters for the diagnosis and follow-up of inflammatory diseases, and inflammation has been found to increase the risk of PONV. However, for patients with hemophilia, no information is currently available on the relationship between the two. In this study, investigators intend to retrospectively analyze the clinical data of patients with hemophilia A in our hospital, explore the clinical value of preoperative NLR and PLR in predicting nausea and vomiting after TKA.

02

Conditions studied

  • Hemophilia A

Keywords

  • Neutrophil
  • Lymphocyte
  • Platelet
  • Hemophilia
  • Post-operative nausea and vomiting
03

In context

Hemophilia A

866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

This study's planned enrollment of 120 is above the median of 80 across 314 observational studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

Qianfoshan Hospital is the lead sponsor of 140 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hemophilia A patients who underwent single knee replacement under general anesthesia in the First Affiliated Hospital of Shandong First Medical University from March 2018 to February 2022

Inclusion criteria

  1. The patients with hemophilia A undergoing unilateral total knee arthroplasty.
  2. The age of the patients ranged from 18 to 70 years.
  3. American Society of Anesthesiologists is graded as I\~III
  4. No history of mental illness
  5. No history of antiemetic and anticholinergic drugs.
  6. No history of serious gastrointestinal diseases.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received long-term steroid treatment
  2. Patients who need more than 2.5 mg neostigmine to reverse muscle relaxants
  3. Patients with previous malignant tumor, malabsorption, morbid obesity, hypogonadism, thyroid and parathyroid diseases and autoimmune diseases.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of PONV in patients with hemophilia A receiving general anesthesia orders for knee arthroplasty

    PONV was defined as the onset of nausea or vomiting within 24 hours after surgery

    Time frame: up to 24 hours after surgery

Secondary outcomes

  1. The amount of postoperative antiemetics

    antiemetics includes ondansetron, metoclopramide, dexamethasone

    Time frame: up to 24 hours after surgery

  2. VAS score after returning to the ward

    postoperative pain can be evaluated using the visual analogue scale (0-10 score, 0: no pain, 10: worst imaginable pain).

    Time frame: immediately after returning to the ward

  3. Usage of PCIA

    the use of postoperative patient controlled intravenous analgesia

    Time frame: up to 24 hours after surgery

07

Study locations

1 site
  • Shandong Provincial Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
    Jinan, Shandong 250000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05636163
Lead sponsor
Qianfoshan Hospital
Responsible party
Lili Cao (Professor, Qianfoshan Hospital) — Principal investigator
First posted
Dec 5, 2022
Start date
Dec 15, 2022 (estimated)
Primary completion
Jan 20, 2023 (estimated)
Completion
Feb 20, 2023 (estimated)
Last update
Dec 5, 2022

Study contacts

Yuelan Wang
Contact
wyldgf@163.com
15953105780
Yuelan Wang
principal investigator · China, Shandong Qianfoshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion